To include your compound in the COVID-19 Resource Center, submit it here.

LCZ696: Additional Phase III data

Additional data from the double-blind, international Phase III PARADIGM-HF trial in 8,442 CHF patients with reduced ejection fraction (<=35%) comparing twice-daily 200 mg LCZ696 vs. standard care with twice-daily 10 mg enalapril were presented at

Read the full 357 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers